rebamipide for use in prevention andor treatment of synucleinopathies

In multivariate analysis, rebamipide was not inferior to PPI in preventing NSAID-induced serious GI complications

The invention relates to a rebamipide tablet The rebamipide tablet is prepared from, by weight, 50%-65% of rebamipide, 15%-45% of diluents,

rebamipide Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis

rebamipide BackgroundAims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers We compared the efficacy of MucostaR